The unraveling of Zosano Pharma has led to a drug delivery deal. With the company filing for bankruptcy in the wake of its rejection by the FDA, Emergex Vaccines has stepped in to provide a new home for its intradermal drug delivery system.
Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation (Fremont, CA).
Closing out the final chapter of its winding 16-year history, Zosano Pharma has sold all of its remaining assets — including the intradermal drug delivery system the company was built on.
The Fremont, CA biotech filed for bankruptcy on Wednesday and is currently operating as a “debtor-in-possession” and intends to rid itself of “substantially all of its assets” over the course of the Chapter 11 case, Zosano said Thursday morning.
FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary...
PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch Emergex’s COVID-19 and Dengue CD8+ T cell...
FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended...
The East Bay company has struggled to win approval of its migraine patch, using a system of micro-needles to deliver the generic drug zolmitriptan.
In April, the migraine-focused biotech announced that it would cull about a third of its workforce — less than a month after the FDA refused to review the company’s resubmission for its migraine treatment patch known as M207. The agency said that the company didn’t adequately respond to the deficiencies identified in the FDA’s initial, 2020 CRL.
FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the...